Last reviewed · How we verify
Bupivacaine HCl Treatment 1c
Bupivacaine HCl Treatment 1c is a Local anesthetic Small molecule drug developed by Durect. It is currently in Phase 2 development for Local anesthesia for surgical procedures, Pain management for postoperative pain.
Bupivacaine HCl is a local anesthetic that works by blocking sodium channels in nerve fibers to prevent the initiation and transmission of nerve impulses.
Bupivacaine HCl is a local anesthetic that works by blocking sodium channels in nerve fibers to prevent the initiation and transmission of nerve impulses. Used for Local anesthesia for surgical procedures, Pain management for postoperative pain.
At a glance
| Generic name | Bupivacaine HCl Treatment 1c |
|---|---|
| Sponsor | Durect |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 2 |
Mechanism of action
This results in a temporary loss of sensation and motor function in the affected area. Bupivacaine HCl is a hydrochloride salt of bupivacaine, a synthetic amide local anesthetic. It is used for regional anesthesia and pain management.
Approved indications
- Local anesthesia for surgical procedures
- Pain management for postoperative pain
Common side effects
- Central nervous system depression
- Cardiovascular effects
- Nausea and vomiting
Key clinical trials
- An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery (PHASE2)
- An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine HCl Treatment 1c CI brief — competitive landscape report
- Bupivacaine HCl Treatment 1c updates RSS · CI watch RSS
- Durect portfolio CI
Frequently asked questions about Bupivacaine HCl Treatment 1c
What is Bupivacaine HCl Treatment 1c?
How does Bupivacaine HCl Treatment 1c work?
What is Bupivacaine HCl Treatment 1c used for?
Who makes Bupivacaine HCl Treatment 1c?
What drug class is Bupivacaine HCl Treatment 1c in?
What development phase is Bupivacaine HCl Treatment 1c in?
What are the side effects of Bupivacaine HCl Treatment 1c?
What does Bupivacaine HCl Treatment 1c target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Durect — full pipeline
- Therapeutic area: All drugs in Pain management
- Indication: Drugs for Local anesthesia for surgical procedures
- Indication: Drugs for Pain management for postoperative pain
- Compare: Bupivacaine HCl Treatment 1c vs similar drugs
- Pricing: Bupivacaine HCl Treatment 1c cost, discount & access